341 related articles for article (PubMed ID: 25709744)
1. Anti-IL5 therapy for asthma and beyond.
Mukherjee M; Sehmi R; Nair P
World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744
[TBL] [Abstract][Full Text] [Related]
2. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
4. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
5. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease.
Fricker M; McDonald VM; Winter NA; Baines KJ; Wark PAB; Simpson JL; Gibson PG
Allergy; 2021 Jul; 76(7):2079-2089. PubMed ID: 33470427
[TBL] [Abstract][Full Text] [Related]
11. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
12. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art.
Vaglio A; Buzio C; Zwerina J
Allergy; 2013 Mar; 68(3):261-73. PubMed ID: 23330816
[TBL] [Abstract][Full Text] [Related]
14. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
15. Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Makiya MA; Khoury P; Kuang FL; Mata AD; Mahmood S; Bowman A; Espinoza D; Kovacs N; Brown T; Holland N; Wetzler L; Ware JM; Dyer AM; Akuthota P; Bochner BS; Chinchilli VM; Gleich GJ; Langford C; Merkel PA; Specks U; Weller PF; Wechsler ME; Prussin C; Fay MP; Klion AD
Allergy; 2023 Jan; 78(1):258-269. PubMed ID: 35971862
[TBL] [Abstract][Full Text] [Related]
16. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.
George L; Brightling CE
Ther Adv Chronic Dis; 2016 Jan; 7(1):34-51. PubMed ID: 26770668
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
20. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
